Clinical trials: Sepsis Severe
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
- Trial name
- TIGRIS (NCT03901807)
- Testing
- Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Severe Sepsis With Septic Shock
A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients
A multicenter, randomized, double-blinded, placebo-controlled study of two dosing frequencies of recombinant Interleukin-7 (CYT107) treatment to restore absolute lymphocyte counts in sepsis patients; IRIS-7B (Immune…
- Trial name
- IRIS-7-B (NCT02640807)
- Testing
- Interleukin-7
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Revimmune
Sepsis, Infection
The Performance of the Mologic Biomarker Panel in Infection
This study is a prospective, single center, observational, cohort study of patients to determine whether the Mologic Biomarker Panel can identify patients with infection from those without, including those with other reasons for…
- Trial name
- NCT03217552
- Testing
- Mologic Biomarker Panel
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- Mologic Ltd
Sepsis
Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis
The objective of this study is to demonstrate that rPAF-AH is safe and reduces 28 day all cause mortality in patients with severe sepsis.
- Trial name
- NCT00037687
- Testing
- rPAF-AH
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- ICOS Corporation
Severe Infection, Sepsis
Evaluation of MDW for Early Detection of Sepsis, Clinical Validity
The purpose of this study is to confirm the clinical validity and the performance of the Monocyte Width Distribution (MDW) parameter to detect the development of sepsis in a prospective study of Emergency Department (ED) adults…
- Conditions
- Severe Infection, Sepsis, Severe Sepsis
- Trial name
- NCT03588325
- Testing
- CBC-DIFF with MDW, PCT, CRP
- Where
- 2 sites in France, Spain
- Volunteers
- 947 people
- Sponsor
- Beckman Coulter, Inc.
Severe Sepsis
Study of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection
A recent study has demonstrated that in low respiratory infections, a strategy using prescription of antibiotics based on the pro-calcitonin level allows decreasing recourse to antibiotics by 47% without prognostic modification.
- Trial name
- Pro-SEPS (NCT01025180)
- Testing
- Procalcitonin level
- Where
- 9 sites in France
- Volunteers
- 62 people
- Sponsor
- Brahms France
Sepsis, Severe Sepsis
TRIAGE: TRIage of Sepsis At emerGency dEpartment
Sepsis is a serious systemic disease defined as a combination of Systemic Inflammation Response Syndrome (SIRS) plus a confirmed or suspected infection.
- Trial name
- TRIAGE (NCT02739152)
- Where
- 14 sites in Belgium, France
- Volunteers
- 602 people
- Sponsor
- BioMérieux
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Sepsis, Septic Shock
An Algorithm Driven Sepsis Prediction Biomarker
A sepsis early warning predictive algorithm, InSight, has been developed and validated on a large, diverse patient cohort. In this prospective study, the ability of InSight to predict severe sepsis patients is investigated.
- Conditions
- Sepsis, Septic Shock, Severe Sepsis
- Trial name
- NCT03015454
- Testing
- Severe Sepsis Prediction, Severe Sepsis Detection
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Dascena
Sepsis, Acute Infection
A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.
The study is a multi-center, prospective, observational clinical study enrolling patients from at least 3 medical centers. Study population will include patients over the age of 18 years.
- Trial name
- NCT06665542
- Where
- 8 sites in United States, Israel
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
Severe Sepsis, Septic Shock
Procalcitonin Monitoring Sepsis Study
The purpose of this study is to investigate the relationship between a procalcitonin decrease over 72 hours and outcome in patients who have severe sepsis or septic shock.
- Trial name
- MOSES (NCT01523717)
- Where
- 13 sites in United States
- Volunteers
- 858 people
- Sponsor
- Brahms AG
Sepsis
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis
The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.
- Trial name
- NCT00143611
- Testing
- Resatorvid
- Where
- 144 sites in United States, Australia and 15 more
- Volunteers
- 277 people
- Sponsor
- Takeda
Sepsis, Adult Disease
Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Washington University
The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in…
- Conditions
- Sepsis, Adult Disease, Severe Sepsis, Emergency Department
- Trial name
- NCT04353388
- Testing
- CBC-DIFF Monocyte Volume Width Distribution (MDW)
- Where
- United States
- Volunteers
- 1,139 people
- Sponsor
- Beckman Coulter, Inc.
Sepsis, Severe Infection
Evaluation of Monocyte Volume Distribution Width (MDW) for Early Detection of Sepsis
The measurement of monocyte volume width distribution (MDW) is intended for use with adult patients presenting to the emergency department (ED), where a CBC with Differential has been ordered, as an aid in the early detection of…
- Trial name
- MDW (NCT03145428)
- Testing
- CBC-Diff Monocyte volume width distribution (MDW)
- Where
- 3 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Beckman Coulter, Inc.
Severe Sepsis
A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
- Trial name
- NCT02960854
- Testing
- Nivolumab
- Where
- 16 sites in United States
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Sepsis
Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis
The rapidity and the quality of fluid resuscitation in patients with severe sepsis are important factors for the prevention of secondary multi-organ failure.
- Trial name
- CRYSTMAS (NCT00464204)
- Testing
- 6 % Hydroxyethylstarch 130/0.4 = "Voluven®", 0.9 % NaCl
- Where
- 24 sites in France, Germany
- Volunteers
- 196 people
- Sponsor
- Fresenius Kabi
Cardiac Arrest, Renal Failure
The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III
To evaluate the effect of automated recording on frequency of recorded scores, number of automated notifications and serious events.
- Conditions
- Cardiac Arrest, Renal Failure, Respiration Failure, Myocardial Infarction
- Trial name
- NCT02973243
- Testing
- Automatic RR Measurement
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- Philips Healthcare
Bacterial Infections, Bone Diseases, Infectious
Fosfomycin I.v. for Treatment of Severely Infected Patients
The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin…
- Conditions
- Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
- Trial name
- FORTRESS (NCT02979951)
- Where
- 50 sites in Austria, Germany and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Infectopharm Arzneimittel GmbH
Sepsis
Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis
The purposes of this study are to determine: 1. Whether drotrecogin alfa (activated) helps children with severe sepsis survive their condition more often or recover faster than children who do not receive drotrecogin alfa…
- Trial name
- NCT00049764
- Testing
- Drotrecogin alfa (activated)
- Where
- 49 sites in United States, Australia and 9 more
- Volunteers
- 474 people
- Sponsor
- Eli Lilly and Company
Severe Sepsis, Septic Shock
GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock
This study is to determine whether the intravenous application of 'Ⅳ-Globulin S inj. (Human Immunoglobulin G)' can reduce mortality in patients with severe sepsis or septic shock.
- Trial name
- NCT01315496
- Testing
- Immunoglobulin G
- Where
- 17 sites in South Korea
- Volunteers
- 214 people
- Sponsor
- Green Cross Corporation